CD8A and breast carcinoma: Kaplanov et al. revealed that therapeutic blockade of IL-1β and inhibition of macrophage recruitment synergized and enabled full CD8+T cell activity in combination with the blockade of the T cell inhibitory molecule, PD-1, promoting significant therapeutic benefit in a murine model of breast cancer [140].